Artax Biopharma has obtained clinical trial authorisation (CTA) from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to assess AX-158 in a Phase IIa study in psoriasis patients.

With the approval, the company intends to commence subject enrolment by the end of this year at study centres in the UK.

The double-blind, randomised, placebo-controlled, proof-of-concept trial is designed to assess the tolerability and safety of AX-158 versus placebo in patients with mild to moderate plaque psoriasis.

Subjects will be randomised into a 2:1 ratio to receive AX-158 or a placebo.

The trial will enrol 30 participants who will receive the treatment for 28 days and a subsequent dosing for another additional 30 days.

An investigational oral, small molecule immunomodulator, AX-158 can adjust T cell responses vital in the healthy functioning of the immune system. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It can also regulate various cytokines that cause diseases without needing immunosuppression. 

Artax Biopharma CEO Joseph Lobacki said: “We are proud to announce the clinical progress of AX-158 and the potential that it may provide a novel treatment to patients managing psoriasis. 

“Additionally, we are excited by the promise of AX-158 as a new standard of care in treating a broad range of autoimmune diseases. 

“In particular, we believe that AX-158 will offer the opportunity to provide a convenient once daily oral therapy that will treat disease while not impairing the ability of the patient’s immune system to function properly.”